As per the latest professional survey report on the global alpha 1 antitrypsin deficiency treatment market by the Transparency Market Research, the industry is anticipated to rise at a significant growth rate of 10.1 % over the forecast period, i.e. 2019 to 2027. Furthermore, the research report also states that the global alpha 1 antitrypsin deficiency treatment market was evaluated at US$ 1.4 billion in the year 2018. Some of the major driving factors that are supplementing the demand in the global alpha 1 antitrypsin deficiency treatment market are increasing prevalence as well as high incidence of various respiratory diseases and increasing awareness amongst public about AAT deficiency and its treatment options.
As per the study by the World Health Organization, approximately 65 million people around the world suffer from chronic obstructive pulmonary disease or COPD. The study also states that around 3 million people die owing to the same disorder all over the world. Along with this, rising government initiatives for developing and expanding the plasma and blood products is also fueling the demand within the global alpha 1 antitrypsin deficiency treatment market in coming years. Moreover, the increase in the prescription for combination therapies is also expected to fuel the growth within the global alpha 1 antitrypsin deficiency treatment market in near future.
On the other hand, the severe side effects associated with the treatment solutions within the global alpha 1 antitrypsin deficiency treatment market, such as chest pain, sinusitis, back pain, and rhinorrhea can restrict the growth within the industry in coming years. Furthermore, high cost associated with therapy as well as the low diagnostic rate for the disease may also negatively impact the growth within the global alpha 1 antitrypsin deficiency treatment market over the forecast period.
The segments within the global alpha 1 antitrypsin deficiency treatment market based on the type of treatment include bronchodilator, oxygen therapy, corticosteroids, and augmentation therapy, including prolastin, glassia, aralast, zemaira or respreeza, among others. The segments in the global alpha 1 antitrypsin deficiency treatment market classified by the route of administration are inhalations, parenteral, and oral. Major end users for the products and solutions offered by the players functional within the global alpha 1 antitrypsin deficiency treatment market include hospitals, specialty clinics, and pharmacies.
To know the scope of our report Get a Sample on Alpha 1 Antitrypsin Deficiency Treatment Market
Leading nations as well as key regions within the global alpha 1 antitrypsin deficiency treatment market include North America (including Canada and the United States), Europe (including the United Kingdom, Italy, Germany, France, Spain, and rest of the Europe), Asia Pacific (including Japan, Australia and New Zealand, China, India, and rest of the Asia Pacific), Latin America (including Mexico, Brazil, and rest of the Latin America), and Middle East and Africa (including South Africa, Gulf Cooperation Council countries, and rest of the Middle East and Africa). Regionally, the North America region leads the global alpha 1 antitrypsin deficiency treatment market in terms of industry share.
Key drivers influencing the growth within the global alpha 1 antitrypsin deficiency treatment market in North America include rising investments by the major players in the region aimed at furthering the research and development activities, enhanced rate of diagnostics for AAT deficiency, and increasing prevalence of respiratory disorders in the region. On the other hand, Europe is anticipated to emerge as the most promising regional market within the global alpha 1 antitrypsin deficiency treatment market over the forecast period. Some of the major factors positively influencing the demand dynamics within the global alpha 1 antitrypsin deficiency treatment market in Europe are increasing research and development initiatives aimed at better treatment of various respiratory disorders, rising demand owing to increased awareness amongst the consumers about AAT deficiency and treatment therapeutics, and increase in the elderly or geriatric population that is more prone to various kinds of respiratory diseases.
Get a glimpse of the in-depth analysis through our Report Brochure
The competitive landscape of the global alpha 1 antitrypsin deficiency treatment market is considered to be highly fragmented, with a number of international players holding a major industry share. Few of the major incumbent players and vendors functional within the global alpha 1 antitrypsin deficiency treatment market include Takeda Pharmaceutical Company Limited, Kamada Pharmaceuticals, AstraZeneca, Pfizer, Inc., LFB Biomedicaments S. A., Grifols, S. A., CSL Behring, GlaxoSmithKline PLC, Boehringer Ingelheim GmbH, and Teva Pharmaceutical Industries Ltd., among others. Several prominent players and manufacturers within the global alpha 1 antitrypsin deficiency treatment market are focused on gaining regulatory approvals for their new products as well as on developing new and innovative products.
Furthermore, some of the key corporate development strategies adopted by the players functional within the global alpha 1 antitrypsin deficiency treatment market include collaborative agreements as well as mergers and acquisitions. For example, Kamada Ltd., extended their strategic supply agreement with the Takeda Pharmaceutical Company Limited in September of 2019. This move will help Kamada to produce Alpha 1 Proteinase Inhibitor for humans called ‘Glassia’ through 2021. Furthermore, Alpha 1 proteinase inhibitor for humans by the CSL Behring called ‘Zemaira’ was approved by the United States Food and Drug Association in April of 2019. This move will allow the company to develop and offer these inhibitors in 4 as well as 5 gram vials in the United States, aimed at the treatment of alpha 1 antitrypsin deficiency.
Expanding operations in future? To get the perfect launch ask for a custom report
The Global Alpha-1 Antitrypsin Deficiency Treatment Market has been segmented as follows:
|
by Treatment Type |
|
|
by Route of Administration |
|
|
by End-User |
|
|
by Region |
|
Alpha 1 antitrypsin deficiency treatment market will expand at a healthy CAGR of 10.1% over the forecast period of 2019 to 2027
Alpha 1 antitrypsin deficiency treatment market is driven by high incidence rate and rising prevalence of various respiratory diseases
North America accounted for a major share of the global alpha 1 antitrypsin deficiency treatment market
The end-use segments in alpha 1 antitrypsin deficiency treatment market are hospitals, specialty clinics, and pharmacies
Key players in the global alpha 1 antitrypsin deficiency treatment market include Takeda Pharmaceutical Company Limited, Kamada Pharmaceuticals, AstraZeneca, Pfizer, Inc., LFB Biomedicaments S.A.
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions
2.2. Research Methodology
3. Executive Summary:
3.1. Global Alpha-1 Antitrypsin Deficiency Treatment: Market Snapshot
3.2. Market Share Analysis by Region, 2018
4. Market Overview
4.1. Introduction
4.1.1. Treatment Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Alpha 1 Antitrypsin Deficiency Treatment Market Analysis and Forecast, 2017–2027
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
5. Key Insights
5.1. Alpha-1 Antitrypsin Deficiency Treatment Market: Value Chain Analysis
5.2. Comparative Brand Analysis
5.3. Porter’s Five Forces Analysis
5.4. Epidemiology: Alpha-1 Antitrypsin Deficiency
5.5. Pipeline Analysis: Alpha-1 Antitrypsin Deficiency Treatment Market
5.6. Clinical Trials: Alpha-1 Antitrypsin Deficiency Treatment Market
6. Alpha-1 Antitrypsin Deficiency Treatment Market Analysis, by Treatment
6.1. Introduction
6.2. Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment
6.3. Alpha-1 Antitrypsin Deficiency Treatment Market Forecast, by Treatment, 2017-2027
6.3.1. Augmentation Therapy
6.3.1.1. Aralast
6.3.1.2. Prolastin
6.3.1.3. Zemaira/Respreeza
6.3.1.4. Glassia
6.3.2. Bronchodilator
6.3.3. Corticosteroids
6.3.4. Oxygen Therapy
6.3.5. Others
6.4. Market Attractiveness Analysis, by Treatment, 2019-2027
7. Alpha-1 Antitrypsin Deficiency Treatment Market Analysis, by End-user, 2017-2027
7.1. Introduction
7.2. Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-User
7.3. Alpha-1 Antitrypsin Deficiency Treatment Market Forecast, by End-user, 2017-2027
7.3.1. Specialty Clinics
7.3.2. Hospitals
7.3.3. Pharmacies
7.4. Market Attractiveness, by End-User, 2019-2027
8. Alpha-1 Antitrypsin Deficiency Treatment Market Analysis, by Route of Administration, 2017-2027
8.1. Introduction
8.2. Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Route of Administration
8.2.1. Alpha-1 Antitrypsin Deficiency Treatment Market Forecast, by Route of Administration , 2017-2027
8.2.2. Parenteral
8.2.3. Inhalation
8.2.4. Oral
8.3. Market Attractiveness by Route of Administration, 2019-2027
9. Alpha-1 Antitrypsin Deficiency Treatment Market Analysis, by Region, 2017-2027
9.1. Global Alpha-1 Antitrypsin Deficiency Treatment Market, Regional Outlook
9.2. Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Region
9.3. Alpha-1 Antitrypsin Deficiency Treatment Market Forecast, by Region, 2017-2027
9.4. Market Attractiveness Analysis, by Region, 2019-2027
10. North America Alpha-1 Antitrypsin Deficiency Treatment Market Analysis
10.1. Market Overview
10.2. Market Analysis, by Treatment
10.2.1. Market Value Share Analysis, by Treatment
10.2.2. Market Value Forecast Forecast, by Treatment, 2017-2027
10.2.2.1. Augmentation Therapy
10.2.2.1.1. Aralast
10.2.2.1.2. Prolastin
10.2.2.1.3. Zemaira/Respreeza
10.2.2.1.4. Glassia
10.2.2.2. Bronchodilator
10.2.2.3. Corticosteroids
10.2.2.4. Oxygen Therapy
10.2.2.5. Others
10.3. Market Value Forecast, by End-user, 2017-2027
10.3.1. Market Value Share Analysis, by End-user
10.3.2. Market Value Forecast Forecast, by End-user
10.3.2.1. Specialty Clinics
10.3.2.2. Hospitals
10.3.2.3. Pharmacies
10.4. Market Value Forecast, by Route of Administration, 2017-2027
10.4.1. Market Value Share Analysis, by Route of Administration
10.4.2. Market Value Forecast Forecast, by Route of Administration
10.4.2.1. Parenteral
10.4.2.2. Inhalation
10.4.2.3. Oral
10.5. Market Value Forecast Forecast, by Country, 2017-2027
10.5.1. Market Value Share Analysis, by Country
10.5.2. Market Value Forecast, by Country, 2017–2027
10.5.2.1. U.S.
10.5.2.2. Canada
10.6. Market Attractiveness Analysis, 2019-2027
10.6.1. By Treatment
10.6.2. By End-user
10.6.3. By Route of Administration
10.6.4. By Country
11. Europe Alpha-1 Antitrypsin Deficiency Treatment Market Analysis
11.1. Market Overview
11.2. Market Analysis, by Treatment
11.2.1. Market Value Share Analysis, by Treatment
11.2.2. Market Value Forecast, by Treatment, 2017-2027
11.2.2.1. Augmentation Therapy
11.2.2.1.1. Aralast
11.2.2.1.2. Prolastin
11.2.2.1.3. Zemaira/Respreeza
11.2.2.1.4. Glassia
11.2.2.2. Bronchodilator
11.2.2.3. Corticosteroids
11.2.2.4. Oxygen Therapy
11.2.2.5. Others
11.3. Market Value Forecast, by End-user
11.3.1. Market Value Share Analysis, by End-user
11.3.2. Market Value Forecast, by End-user, 2017-2027
11.3.2.1. Specialty Clinics
11.3.2.2. Hospitals
11.3.2.3. Pharmacies
11.4. Market Value Forecast, by Route of Administration, 2017-2027
11.4.1. Market Value Share Analysis, by Route of Administration
11.4.2. Market Value Forecast, by Route of Administration
11.4.2.1. Parenteral
11.4.2.2. Inhalation
11.4.2.3. Oral
11.5. Market Value Forecast, by Country
11.5.1. Market Value Share Analysis, by Country
11.5.2. Market Value Forecast, by Country, 2017-2027
11.5.2.1. U.K.
11.5.2.2. Germany
11.5.2.3. France
11.5.2.4. Italy
11.5.2.5. Spain
11.5.2.6. Rest of Europe
11.6. Market Attractiveness Analysis, 2019-2027
11.6.1. By Treatment
11.6.2. By End-user
11.6.3. By Route of Administration
11.6.4. By Country
12. Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Analysis
12.1. Market Overview
12.2. Market Analysis, by Treatment
12.2.1. Market Value Share Analysis, by Treatment
12.2.2. Market Value Forecast, by Treatment, 2017-2027
12.2.2.1. Augmentation Therapy
12.2.2.1.1. Aralast
12.2.2.1.2. Prolastin
12.2.2.1.3. Zemaira/Respreeza
12.2.2.1.4. Glassia
12.2.2.2. Bronchodilator
12.2.2.3. Corticosteroids
12.2.2.4. Oxygen Therapy
12.2.2.5. Others
12.3. Market Value Forecast, by End-user
12.3.1. Market Value Share Analysis, by End-user
12.3.2. Market Value Forecast, by End-user, 2017-2027
12.3.2.1. Specialty Clinics
12.3.2.2. Hospitals
12.3.2.3. Pharmacies
12.4. Market Value Forecast, by Route of Administration
12.4.1. Market Value Share Analysis, by Route of Administration
12.4.2. Market Value Forecast, by Route of Administration, 2017-2027
12.4.2.1. Parenteral
12.4.2.2. Inhalation
12.4.2.3. Oral
12.5. Market Value Forecast, by Country, 2017-2027
12.5.1. Market Value Share Analysis, by Country
12.5.2. Market Value Forecast, by Country, 2017-2027
12.5.2.1. China
12.5.2.2. Japan
12.5.2.3. India
12.5.2.4. Australia & New Zealand
12.5.2.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis, 2019-2027
12.6.1. By Treatment
12.6.2. By End-user
12.6.3. By Route of Administration
12.6.4. By Country
13. Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Analysis
13.1. Market Overview
13.2. Market Analysis, by Treatment
13.2.1. Market Value Share Analysis, by Treatment
13.2.2. Market Value Forecast, by Treatment, 2017-2027
13.2.2.1. Augmentation Therapy
13.2.2.1.1. Aralast
13.2.2.1.2. Prolastin
13.2.2.1.3. Zemaira/Respreeza
13.2.2.1.4. Glassia
13.2.2.2. Bronchodilator
13.2.2.3. Corticosteroids
13.2.2.4. Oxygen Therapy
13.2.2.5. Others
13.3. Market Value Forecast, by End-user, 2017-2027
13.3.1. Market Value Share Analysis, by End-user
13.3.2. Market Value Forecast, by End-user, 2017-2027
13.3.2.1. Specialty Clinics
13.3.2.2. Hospitals
13.3.2.3. Pharmacies
13.4. Market Value Forecast, by Route of Administration
13.4.1. Market Value Share Analysis, by Route of Administration
13.4.2. Market Value Forecast, by Route of Administration, 2017-2027
13.4.2.1. Parenteral
13.4.2.2. Inhalation
13.4.2.3. Oral
13.5. Market Value Forecast, by Country
13.5.1. Market Value Share Analysis, by Country
13.5.2. Market Value Forecast, by Country, 2017-2027
13.5.2.1. Brazil
13.5.2.2. Mexico
13.5.2.3. Rest of LATAM
13.6. Market Attractiveness Analysis, 2019-2027
13.6.1. By Treatment
13.6.2. By End-user
13.6.3. By Route of Administration
13.6.4. By Country
14. Middle East and Africa Alpha-1 Antitrypsin Deficiency Treatment Market Analysis
14.1. Market Overview
14.2. Market Analysis, by Treatment
14.2.1. Market Value Share Analysis, by Treatment
14.2.2. Market Value Forecast, by Treatment, 2017-2027
14.2.2.1. Augmentation Therapy
14.2.2.1.1. Aralast
14.2.2.1.2. Prolastin
14.2.2.1.3. Zemaira/Respreeza
14.2.2.1.4. Glassia
14.2.2.2. Bronchodilator
14.2.2.3. Corticosteroids
14.2.2.4. Oxygen Therapy
14.2.2.5. Others
14.3. Market Value Forecast, by End-user
14.3.1. Market Value Share Analysis, by End-user
14.3.2. Market Value Forecast, by End-user, 2017-2027
14.3.2.1. Specialty Clinics
14.3.2.2. Hospitals
14.3.2.3. Pharmacies
14.4. Market Value Forecast, by Route of Administration
14.4.1. Market Value Share Analysis, by Route of Administration
14.4.2. Market Value Forecast, by Route of Administration, 2017-2027
14.4.2.1. Parenteral
14.4.2.2. Inhalation
14.4.2.3. Oral
14.5. Market Value Forecast, by Country
14.5.1. Market Value Share Analysis, by Country
14.5.2. Market Value Forecast, by Country, 2017-2027
14.5.2.1. GCC Countries
14.5.2.2. South Africa
14.5.2.3. Rest of MEA
14.6. Market Attractiveness Analysis, 2019-2027
14.6.1. By Treatment
14.6.2. By End-user
14.6.3. By Route of Administration
14.6.4. By Country
15. Competition Landscape
15.1. Alpha-1 Antitrypsin Deficiency Treatment Market Share Analysis, by Company (2016)
15.2. Company Profiles
15.2.1. Grifols, S.A.
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Product Portfolio
15.2.1.3. SWOT Analysis
15.2.1.4. Strategic Overview
15.2.2. AstraZeneca
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Product Portfolio
15.2.2.3. SWOT Analysis
15.2.2.4. Strategic Overview
15.2.3. Teva Pharmaceutical Industries Ltd.
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Product Portfolio
15.2.3.3. SWOT Analysis
15.2.3.4. Strategic Overview
15.2.4. Boehringer Ingelheim GmbH
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Product Portfolio
15.2.4.3. SWOT Analysis
15.2.4.4. Strategic Overview
15.2.5. GlaxoSmithKline Plc.
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Product Portfolio
15.2.5.3. SWOT Analysis
15.2.5.4. Strategic Overview
15.2.6. CSL Behring LLC
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Product Portfolio
15.2.6.3. SWOT Analysis
15.2.6.4. Strategic Overview
15.2.7. Takeda Pharmaceutical Company Limited
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Product Portfolio
15.2.7.3. SWOT Analysis
15.2.7.4. Strategic Overview
15.2.8. Pfizer Inc.
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Product Portfolio
15.2.8.3. SWOT Analysis
15.2.8.4. Strategic Overview
15.2.9. LFB Biomedicaments S.A.
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Product Portfolio
15.2.9.3. SWOT Analysis
15.2.9.4. Strategic Overview
15.2.10. Kamada Ltd
15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.10.2. Product Portfolio
15.2.10.3. SWOT Analysis
15.2.10.4. Strategic Overview
List of Tables
Table 01: Comparative Analysis of Approved Alpha-1 Antitrypsin Replacement Therapy Brands
Table 02: Pipeline Analysis: Alpha-1 Antitrypsin Deficiency Treatment Market
Table 03: Clinical Trials: Alpha-1 Antitrypsin Deficiency Treatment Market
Table 04: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Treatment, 2017–2027
Table 05: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by End-user, 2017–2027
Table 06: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Route of Administration, 2017–2027
Table 07: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Region, 2017–2027
Table 08: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Treatment, 2017–2027
Table 09: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by End-user, 2017–2027
Table 10: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Route of Administration, 2017–2027
Table 11: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Country, 2017–2027
Table 12: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Treatment, 2017–2027
Table 13: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by End-user, 2017–2027
Table 14: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Route of Administration, 2017–2027
Table 15: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Country, 2017–2027
Table 16: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Treatment, 2017–2027
Table 17: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by End-user, 2017–2027
Table 18: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Route of Administration, 2017–2027
Table 19: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Country, 2017–2027
Table 20: Table 17: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Treatment, 2017–2027
Table 21: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by End-user, 2017–2027
Table 22: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Route of Administration, 2017–2027
Table 23: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Country, 2017–2027
Table 24: Middle East & Africa Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Treatment Type, 2017–2027
Table 25: Middle East & Africa Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by End-user, 2017–2027
Table 26: Middle East & Africa Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Route of Administration, 2017–2027
Table 27: Middle East & Africa Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, by Country, 2017–2027
List of Figures
Figure 01: Alpha-1 Antitrypsin Deficiency Treatment Market Snapshot
Figure 02: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast Forecast and Y-o-Y Growth (%), 2017–2027
Figure 03: Market Value Share By Treatment Type (2018)
Figure 04: Market Value Share By End-user (2018)
Figure 05: Market Value Share By Route of Administration (2018)
Figure 06: Market Value Share By Region(2018)
Figure 07: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
Figure 08: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Augmentation Therapy, 2017–2027
Figure 09: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Bronchodilators, 2017–2027
Figure 10: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Corticosteroids, 2017–2027
Figure 11: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Oxygen Therapy, 2017–2027
Figure 12: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027
Figure 13: Global Aralast Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2027
Figure 14: Global Prolastin Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2027
Figure 15: Global Zemaira/Respreeza Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2027
Figure 16: Global Glassia Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2027
Figure 17: Global Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Treatment, 2019-2027
Figure 18: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-user, 2018 and 2027
Figure 19: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Specialty Clinics, 2017–2027
Figure 20: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospitals, 2017–2027
Figure 21: Global Alpha-1 Antitrypsin Deficiency Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Pharmacies, 2017–2027
Figure 22: Global Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by End-user, 2019-2027
Figure 23: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Route of Administration, 2018 and 2027
Figure 24: Global Parenteral Market Revenue, US$ Mn,2017-2027
Figure 25: Global Inhalation Market Revenue, US$ Mn, 2017-2027
Figure 26: Global Oral Market Revenue, US$ Mn, 2017–2027
Figure 27: Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Route of Administration, 2019-2027
Figure 28: Global Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Region, 2018 and 2027
Figure 29: Global Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Region, 2019-2027
Figure 30: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, 2017–2027
Figure 31: North America Market Attractiveness Analysis, by Country, 2019-2027
Figure 32: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
Figure 33: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-user, 2018 and 2027
Figure 34: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Route of Administration, 2018 and 2027
Figure 35: North America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Country, 2018 and 2027
Figure 36: North America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Treatment, 2019-2027
Figure 37: North America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by End-user, 2019-2027
Figure 38: North America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Route of Administration, 2019-2027
Figure 39: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, 2017–2027
Figure 40: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Country, 2019-2027
Figure 41: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
Figure 42: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-user, 2018 and 2027
Figure 43: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Route of Administration, 2018 and 2027
Figure 44: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Country, 2018 and 2027
Figure 45: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Treatment, 2019-2027
Figure 46: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by End-user, 2019-2027
Figure 47: Europe Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Route of Administration, 2019-2027
Figure 48: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, 2017–2027
Figure 49: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Country, 2019-2027
Figure 50: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
Figure 51: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-user, 2018 and 2027
Figure 52: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Route of Administration, 2018 and 2027
Figure 53: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Country, 2018 and 2027
Figure 54: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Treatment, 2019-2027
Figure 55: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by End-user, 2019-2027
Figure 56: Asia Pacific Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Route of Administration, 2019-2027
Figure 57: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, 2017–2027
Figure 58: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Country, 2019-2027
Figure 59: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
Figure 60: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by End-user, 2018 and 2027
Figure 61: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Route of Administration, 2018 and 2027
Figure 62: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Value Share Analysis, by Country, 2018 and 2027
Figure 63: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Treatment, 2019-2027
Figure 64: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by End-user, 2019-2027
Figure 65: Latin America Alpha-1 Antitrypsin Deficiency Treatment Market Attractiveness Analysis, by Route of Administration, 2019-2027
Figure 66: Middle East & Africa Alpha-1 Antitrypsin Deficiency Treatment Market Value Forecast, 2017–2027
Figure 67: Middle East & Africa Market Attractiveness Analysis, by Country, 2019-2027
Figure 68: Middle East & Africa Market Value Share Analysis, by Treatment, 2018 and 2027
Figure 69: Middle East & Africa Market Value Share Analysis, by End-user, 2018 and 2027
Figure 70: Middle East & Africa Market Value Share Analysis, by Route of Administration, 2018 and 2027
Figure 71: Middle East & Africa Market Value Share Analysis, by Country, 2018 and 2027
Figure 72: Middle East & Africa Market Attractiveness Analysis, by Treatment, 2019-2027
Figure 73: Middle East & Africa Market Attractiveness Analysis, by End-user, 2019-2027
Figure 73: Middle East & Africa Market Attractiveness Analysis, by Route of Administration, 2019-2027
Figure 75: Global Alpha-1 Antitrypsin Deficiency Treatment Market Share Analysis, by Company (2018)
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Alpha 1 Antitrypsin Deficiency Treatment Market
*86 figures and 60 tables includes